A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

To be considered for this study, you would generally need to have a specific type of advanced gastrointestinal cancer, such as pancreatic, bile duct, bowel, or stomach cancer, that doctors cannot remove with surgery or has spread. You must also have already received some treatment for your cancer in the past.

There are also some health conditions that would mean you couldn't join the study. For example, if you have certain lung problems (like a history of severe lung inflammation), serious heart conditions, or other active cancers that are still growing or have needed recent treatment, you might not be able to take part. Also, if you have an autoimmune disease that has needed strong medication recently, or if you've recently had major surgery, you might be excluded.

If you have HIV, you might still be able to join if your HIV infection is well-controlled with medication. The doctors running the study will carefully check all these points to make sure the study is safe and suitable for you.

If you decide to take part in this study, you will receive the study medicine, raludotatug deruxtecan (R-DXd). The doctors and nurses will closely monitor your health and the effects of the treatment. This will involve regular visits to the clinic for check-ups, blood tests, scans (like CT or MRI scans) to see how your cancer is responding, and to check for any side effects.

You'll also have physical exams and discussions with the study team about how you're feeling. The frequency and duration of these visits will be explained in detail by the study team, but generally, studies like this involve regular appointments for many months, and sometimes follow-up for longer, even after you stop receiving the study medicine. Throughout the study, the team will ensure you understand what's required at each step.